Introduction Despite recent advances in migraine treatment there is a need for therapies with
higher clinical efficacy and/or fewer side effects. Triptans (5-HT1B/1D/1F agonists) are …

Background The treatment of migraine is impeded by several difficulties, among which
insufficient headache relief, side effects, and risk for developing medication overuse …

Migraine is a complex neurovascular syndrome, causing a unilateral pulsating headache
with accompanying symptoms. The past four decades have contributed immensely to our …

The last decade has witnessed a tremendous progress in the acute therapy of migraine, with
sumatriptan, belonging to a new class of drugs, now known as 5-HT1B/1D/1F receptor …

Migraine headache is a pervasive but poorly understood primary pain disorder. Sumatriptan
and the 'triptan'class of serotonin receptor subtype-selective drugs have well-established …

Objective To review and highlight current literature on emerging acute migraine treatments,
focusing on CGRP receptor antagonists, gepants, and 5‐HT1F receptor agonists (ditans) …

Objective To evaluate the potential for pharmacokinetic interaction and the safety and
tolerability when ubrogepant and sumatriptan are coadministered in a Phase 1 study in …

Introduction: Migraine is the most common of all neurological disorders. A breakthrough in
migraine treatment emerged in the early nineties with the introduction of 5-HT1B/D receptor …

The current approach to antimigraine therapy comprises potent serotonin 5-HT 1B/1D
receptor agonists collectively termed triptans. Sumatriptan was the first of these compounds …

Introduction: Migraine is one of the most common neurological disorders. Nowadays, the 5-
HT1B/1D receptor agonists, namely triptans, are considered as the standard of care for …